| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Inventiva S.A (PA: IVA)
IVA Technical Analysis
5
| As on 3rd Mar 2026 IVA STOCK Price closed @ 5.09 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.03 & Strong Buy for SHORT-TERM with Stoploss of 2.25 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IVASTOCK Price
| Open | 5.18 | Change | Price | % |
| High | 5.20 | 1 Day | -0.22 | -4.14 |
| Low | 5.01 | 1 Week | -0.53 | -9.43 |
| Close | 5.09 | 1 Month | -0.06 | -1.17 |
| Volume | 611483 | 1 Year | 2.64 | 107.76 |
| 52 Week High 5.98 | 52 Week Low 2.10 | ||||
PA France Most Active Stocks
| FTI | 5.91 | -1.66% |
| VIEDS | 0.72 | 4.35% |
| ENGI | 27.01 | -5.56% |
| TTE | 68.10 | -1.82% |
| CS | 38.96 | -3.87% |
| ACA | 17.58 | -4.40% |
| ALNEV | 0.00 | % |
| CGG | 0.69 | -2.82% |
| ORA | 17.81 | -0.34% |
| LAT | 0.02 | % |
PA France Top Gainers Stocks
PA France Top Losers Stocks
| IVA Daily Charts |
IVA Intraday Charts |
Whats New @ Bazaartrend |
IVA Free Analysis |
|
|
IVA Important Levels Intraday
| RESISTANCE | 5.46 |
| RESISTANCE | 5.34 |
| RESISTANCE | 5.27 |
| RESISTANCE | 5.19 |
| SUPPORT | 4.99 |
| SUPPORT | 4.91 |
| SUPPORT | 4.84 |
| SUPPORT | 4.72 |
IVA Forecast March 2026
| 4th UP Forecast | 6.01 |
| 3rd UP Forecast | 5.72 |
| 2nd UP Forecast | 5.53 |
| 1st UP Forecast | 5.35 |
| 1st DOWN Forecast | 4.83 |
| 2nd DOWN Forecast | 4.65 |
| 3rd DOWN Forecast | 4.46 |
| 4th DOWN Forecast | 4.17 |
IVA Weekly Forecast
| 4th UP Forecast | 5.34 |
| 3rd UP Forecast | 5.26 |
| 2nd UP Forecast | 5.21 |
| 1st UP Forecast | 5.16 |
| 1st DOWN Forecast | 5.02 |
| 2nd DOWN Forecast | 4.97 |
| 3rd DOWN Forecast | 4.92 |
| 4th DOWN Forecast | 4.84 |
IVA Forecast2026
| 4th UP Forecast | 13.18 |
| 3rd UP Forecast | 10.59 |
| 2nd UP Forecast | 8.98 |
| 1st UP Forecast | 7.38 |
| 1st DOWN Forecast | 2.8 |
| 2nd DOWN Forecast | 1.2 |
| 3rd DOWN Forecast | -0.41 |
| 4th DOWN Forecast | -3 |
Inventiva S.A ( PA France Symbol : IVA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IVA Business Profile
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France. Address: 50 rue de Dijon, Daix, France, 21121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service